- Home
- ZD vs ATAI Comparison
ZD vs ATAI Comparison
Compare ZD & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZD | ATAI |
|---|---|---|
| Founded | 1995 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.4B |
| IPO Year | 1999 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ZD | ATAI |
|---|---|---|
| Price | $37.34 | $3.64 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | ★ $37.00 | $14.33 |
| AVG Volume (30 Days) | 522.4K | ★ 4.1M |
| Earning Date | 02-23-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 92.61 | N/A |
| EPS | ★ 2.65 | N/A |
| Revenue | ★ $1,457,379,000.00 | $3,018,000.00 |
| Revenue This Year | $7.37 | $943.18 |
| Revenue Next Year | $2.92 | N/A |
| P/E Ratio | $14.32 | ★ N/A |
| Revenue Growth | 5.70 | ★ 811.78 |
| 52 Week Low | $28.55 | $1.15 |
| 52 Week High | $56.48 | $6.75 |
Technical Indicators
Market Signals| Indicator | ZD | ATAI |
|---|---|---|
| Relative Strength Index (RSI) | 60.18 | 36.54 |
| Support Level | $35.47 | $3.60 |
| Resistance Level | $37.60 | $3.85 |
| Average True Range (ATR) | 1.52 | 0.21 |
| MACD | 0.23 | -0.02 |
| Stochastic Oscillator | 80.85 | 6.80 |
Price Performance
Historical ComparisonAbout ZD Ziff Davis Inc.
Ziff Davis Inc is a focused digital media and internet company whose portfolio includes brands in technology, entertainment, shopping, health, cybersecurity, and martech. It has two reportable segments: Digital Media and Cybersecurity and Martech. The company's brands include Mashable, Ookla, Offers.com, IGN, and VPN among others. The majority of revenue is generated from Digital Media.
About ATAI ATAI Life Sciences N.V.
Atai Beckley NV is a clinical-stage biopharmaceutical company. It aims to develop mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 and BPL-003 for the treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder.